Refine by
Blood Grouping Product Articles & Analysis
30 news found
MedSource Labs Moves the Needle in the Peripheral Safety IV Market With the announcement of ClearSafe Comfort® and TrueSafe Comfort® Blood Control IV Catheters with groundbreaking active check valve ...
Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched blood product widely used in cell therapy, the maximum shelf life of which is 48h when supplied fresh. The collection, processing, and shipment of fresh apheresis ...
ZipThaw is a blood product thawer that uses revolutionary dry technology to quickly thaw blood products for patients in need. ZipThaw is dry, so there’s no messes like with water baths, and fast, so you can increase your thawed plasma throughput — it’s also easy for staffers to use. With simple thawing, staffers can spend their time elsewhere on other critical tasks. Last ...
We’ve been on the road introducing ZipThaw, the revolutionary blood product thawing device, to military and civilian clinicians. This week we’re in Washington DC with Mark Rosenfeld of Genesis BPS. Here are some outtakes from the various shows and exhibitions. We’re grateful for the interest and flurry of new orders. ZipThaw is currently in use across the world! ...
For decades, medical professionals have used slow, cumbersome, imprecise water baths to thaw plasma. It’s time for a better way! Introducing ZipThaw: a dry, portable, rapid thawing device combined with our disposable ZipSleeve® anti-contamination barrier with heat sensors. As an alternative to water baths, dry plasma thawing is a groundbreaking innovation that unlocks numerous ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce the appointment of Mr. Peter Pavlin, P.Eng. to the position of Vice President Operations. Mr. Pavlin earned his Bachelor of Applied Science and Master of Engineering degrees in Mechanical Engineering from the University of Toronto, Canada’s top ranked ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce Mr. Richard (“Rick”) Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. CytoSorbents will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021. Dr. ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE: 2VFO.F) is pleased to announce that it has entered into a settlement agreement (the “Settlement Agreement”) with Aspire Health Science, LLC ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) announces that it has closed its previously announced non-brokered private placement of units (“Units”) announced on February 2, 2022, for gross proceeds of $1,204,849.92 (the “Offering”). The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it has signed a Global Master Services Agreement with My Next Health (“MNH”), and has, subject to TSXV approval, obtained a subscription from My Next Health in the amount of USD $150,000 at CAD $0.25 per Unit. My Next Health Inc. (“MNH”) is the ...
Kurin. Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years. “AllSpire Health GPO and Kurin are committed to patient safety by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing ...
Following technology transfer, the team will create a new product by combining the two formulations, beginning with human islets. Thereafter, the team will complete preclinical studies to demonstrate the product’s characteristics in vivo, with a plan to move forward with first-in-human testing. ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce the source document verification process has been completed and the Company has soft locked the HS 12-01 database. Next, each of the principal investigators will sign off the source documentation of the subjects they followed. Following the sign off by all principal ...
Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis Health at Doctors Hospital, staff at University of Maryland Capitol Region Medical Center and Director of the Chiari Syringomyelia Foundation Greater Metropolitan Washington Chapter, where he is focused on the development of the understanding and treatment of deformity induced ...
The collaboration allows Focal Healthcare to develop a smart 3D ultrasound imaging platform for point of care use. TORONTO, CANADA – Focal Healthcare, known globally as a leading innovator of image-guided prostate cancer technology, is diversifying their product line by developing an AI-based 3D ultrasound imaging platform. Focal Healthcare has licensed patents from the Centre for Imaging ...
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in ...
“It is interesting to listen to Peter following his treatment, compare the study results published about ACP and Mavacamten with respect to dilated cardiomyopathy, and then compare the market capitalization of Hemostemix ($11.5 Million) to the $13.1 Billion takeover of Myokardia by Bristol Myers Squibb because both therapeutics resulted in an improvement in ejection fraction, both ...
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen's QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients. ...